Pharmaceutical Research and Manufacturers of America v. Walsh, Acting Commissioner, Maine Department of Human Services
The Supreme Court let Maine's prescription-drug discount program go forward for now, ruling that a drug-industry trade group had not shown it was likely to win its claim that the program was blocked by federal Medicaid law or unconstitutionally burdened interstate commerce.
The decision means states have more room to experiment with programs that use their leverage over Medicaid drug purchases to negotiate lower prices for all residents, though the Court left the door open for the manufacturers to challenge the program again once it is actually put into practice.
“At this stage of the litigation, petitioner has not carried its burden of showing a probability of success on the merits of its claims.”
The Court's bottom-line conclusion on why the preliminary injunction against Maine's program could not stand.
How it got here: A federal trial court issued a preliminary injunction blocking the program before it began; the First Circuit reversed, and the Supreme Court agreed to review the case.
The Case in Depth
What happened
Maine created the "Maine Rx" program to get cheaper prescription drugs for its residents, including many who are not on Medicaid. The state asked drug manufacturers to pay rebates funding discounts for all qualified residents; companies that refused would face extra "prior authorization" paperwork before their drugs could be reimbursed under Maine's Medicaid program. A trade association representing most major drug manufacturers, none based in Maine, sued to block the program before it even started, arguing it improperly used the Medicaid program to pressure companies over non-Medicaid sales and unlawfully reached into out-of-state pricing decisions.
The question before the Court
Could Maine require drug companies to negotiate rebates for all state residents, or use extra approval hurdles on their Medicaid sales if they refused, without running afoul of federal Medicaid law or the Constitution's limits on regulating interstate commerce?
The Court's answer
Not clearly — the Court ruled that the drug manufacturers had not shown they were likely to win, so the program could go forward for now. On preemption, the Court said Maine's rebate-and-prior-authorization scheme plausibly serves Medicaid-related goals, like helping needy uninsured residents and controlling costs, and that only a severe curtailment of Medicaid patients' drug access — not any modest inconvenience — would justify blocking a state program under federal Medicaid law.
On the Commerce Clause claim, the Court found no violation because Maine's program does not set prices for out-of-state transactions and does not give any competing manufacturer a special advantage. Because the record at this early stage was incomplete and no factual hearing had occurred, the Court limited its holding to this preliminary posture, leaving room for the manufacturers to challenge the program again once it is actually in operation.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Uninsured and underinsured residents of Maine can keep pursuing discounted prescription drugs while the case proceeds, and other states weighing similar rebate programs gained a measure of legal breathing room. Drug manufacturers, meanwhile, still face the threat of added paperwork hurdles on their Medicaid sales if they refuse to offer rebates on sales to everyone else.
What changes now
The case returns to the lower courts, where the manufacturers may pursue further factual development and could renew their challenge if evidence emerges that the program actually harms Medicaid patients' access to needed drugs. The decision does not finally resolve whether Maine Rx is lawful, and the opinion notes that the federal Medicaid agency may still weigh in on whether the program requires separate approval as an amendment to Maine's Medicaid plan.
What this does not decide
The Court repeatedly stressed that it was only deciding whether the trade association had shown enough to justify blocking the program before it started, not whether Maine Rx is ultimately valid. It expressly left open whether the federal Medicaid agency must approve the program and whether it could later be found unlawful if evidence shows it actually harms patients' access to drugs.
Concurrences and dissents
Concurrence — Justice Breyer
Justice Breyer agreed the injunction should be vacated but thought the district court's standard understated how strong a showing the manufacturers needed to make, requiring proof the program would seriously compromise important federal interests. He emphasized that the Secretary of Health and Human Services' views deserve significant weight and urged the district court to seek those views, including through the doctrine of primary jurisdiction, before any renewed injunction request.
Concurrence — Justice Scalia
Justice Scalia would have rejected both claims outright. On preemption, he argued the only remedy for a state's noncompliance with Medicaid conditions is the Secretary cutting off funding, not a private preemption lawsuit, unless the Secretary's own enforcement decision is arbitrary or unlawful. He also rejected the Commerce Clause claim as resting on a doctrine he views as having no basis in the Constitution's text.
Concurrence — Justice Thomas
Justice Thomas concluded Maine Rx is not preempted at all, disagreeing with the plurality's reasoning. He argued the Medicaid Act gives states broad, largely unqualified discretion to impose prior authorization, and that because an agency administers the Act, deference to the Secretary's own non-preemptive interpretation forecloses any obstacle-preemption claim from succeeding.
Dissent in part — Justice O'Connor
“By imposing prior authorization on Maine’s Medicaid population to achieve wholly non-Medicaid related goals, Maine Rx “stands as an obstacle to the accomplishment and execution of the full purposes and objectives” of the federal Medicaid Act.”O'Connor's core objection that the program burdens Medicaid patients without any Medicaid-related justification.
Justice O'Connor agreed states cannot burden Medicaid recipients with prior authorization absent a genuine Medicaid purpose, but she thought the district court correctly found no such purpose here, since the program openly aimed to lower drug prices for all residents regardless of need. She would have upheld the injunction and rejected the plurality's speculative justifications as unsupported by the trial record.
How the Court got there
The legal reasoning, step by step
- Because the district court had not held a trial or resolved any factual disputes, the Court framed the question narrowly: whether the manufacturers had shown a probability of success on the merits sufficient to justify a preliminary injunction, not whether the program is ultimately lawful.
- The Court applied a presumption that state statutes are valid, placing the burden on the challengers to show the federal Medicaid law likely displaced Maine's program under the doctrine of obstacle preemption -- the idea that a state law can be blocked if it stands in the way of a federal law's purposes, even without directly conflicting with its text.
- The Court found the manufacturers had not shown the absence of any Medicaid-related purpose, since the program could plausibly help medically needy residents, keep borderline patients healthy enough to avoid needing Medicaid later, and let Maine use prior authorization the way private insurers already do to control drug costs.
- The Court concluded that the district court had used too strict a preemption standard by treating any impediment to a patient's drug access, no matter how minor, as enough to block the program; instead, only a severe curtailment of access to Medicaid drugs would justify preemption.
- On the Commerce Clause claim, the Court applied precedent barring states from directly fixing out-of-state prices or discriminating against out-of-state competitors, and found Maine's rebate requirement did neither, because it did not set the price of any out-of-state sale and did not give any competitor of participating manufacturers a special benefit.
- Weighing the record as it stood, the Court concluded the manufacturers had not carried their burden of showing a likelihood of success on either claim, so the preliminary injunction could not be sustained on this record.
Doctrinal impact
Cases affected by this decision
Distinguishes Baldwin v. G. A. F. Seelig, Inc. (294 U.S. 511)
The Court said this price-control case did not apply because Maine's law does not set the price of any out-of-state sale.
Distinguishes Healy v. Beer Institute (491 U.S. 324)
The Court found this price-affirmation case inapplicable because Maine does not tie in-state prices to out-of-state prices.
Distinguishes West Lynn Creamery, Inc. v. Healy (512 U.S. 186)
The Court said this milk-tax case did not apply because Maine's rebate program imposes no disparate burden on competitors.
Reaffirms Alexander v. Choate (469 U.S. 287)
The Court relied on this case's rule that states have broad discretion over Medicaid benefits so long as meaningful access continues.
Reaffirms Beal v. Doe (432 U.S. 438)
The Court cited this case for the principle that states may curtail Medicaid coverage for reasons unrelated to Medicaid itself.
Reaffirms New York State Dept. of Social Servs. v. Dublino (413 U.S. 405)
The Court relied on this case's presumption against preemption when state and federal governments pursue common purposes.